Edited Oct 21, 2026

Right2Try does not sell Ivermectin, Fenbendazole, Mebendazole, Methylene Blue, Hydroxychloroquine, or any other supplements on this website or by Email.

The Giant Source List

Welcome to The Giant Source List, an absurdly long compilation of scientific sources exploring the potential of Ivermectin, Fenbendazole, Mebendazole, Methylene Blue, and Hydroxychloroquine to shrink cancer tumors. These drugs, originally developed for parasitic infections (except Methylene Blue, a dye with medicinal uses, and Hydroxychloroquine, an antimalarial also used for autoimmune conditions), have shown promise in preclinical studies—mostly in labs and animal models—but human evidence is still limited.

Sources

Ivermectin

124 sources

Showing 6 of 124

pubmed.ncbi.nlm.nih.gov Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin. pubmed.ncbi.nlm.nih.gov Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures. pubmed.ncbi.nlm.nih.gov Apoptosis-Inducing and Proliferation-Inhibiting Effects of Doramectin on Mz-ChA-1 Human Cholangiocarcinoma Cells. pubmed.ncbi.nlm.nih.gov Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. pubmed.ncbi.nlm.nih.gov Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches. pubmed.ncbi.nlm.nih.gov Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer.

Fenbendazole

39 sources

Showing 6 of 39

pubmed.ncbi.nlm.nih.gov Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study. pubmed.ncbi.nlm.nih.gov Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer Cells. pubmed.ncbi.nlm.nih.gov Oral Fenbendazole for Cancer Therapy in Humans and Animals. pubmed.ncbi.nlm.nih.gov Synergistic intravesical instillation for bladder cancer: CRISPR-Cas13a and fenbendazole combination therapy. pubmed.ncbi.nlm.nih.gov Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma. pubmed.ncbi.nlm.nih.gov Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer.

Mebendazole

125 sources

Showing 6 of 125

pubmed.ncbi.nlm.nih.gov Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in vivo permeation analysis. pubmed.ncbi.nlm.nih.gov USP5 Binds and Stabilizes EphA2 to Increase Nasopharyngeal Carcinoma Radioresistance. pubmed.ncbi.nlm.nih.gov Mebendazole Exerts Anticancer Activity in Ovarian Cancer Cell Lines via Novel Girdin-Mediated AKT/IKKα/β/NF-κB Signaling Axis. pubmed.ncbi.nlm.nih.gov Albumin and Polysorbate-80 Coated Sterile Nanosuspensions of Mebendazole for Glioblastoma Therapy. pubmed.ncbi.nlm.nih.gov Transcriptome analysis displays new molecular insights into the mechanisms of action of Mebendazole in gastric cancer cells. pubmed.ncbi.nlm.nih.gov Repurposing flubendazole for glioblastoma ferroptosis by affecting xCT and TFRC proteins.

Methylene Blue

547 sources

Showing 6 of 547

pubmed.ncbi.nlm.nih.gov Systemic antitumor immune response of doped yttria nanoscintillators under low-dose x-ray irradiation. pubmed.ncbi.nlm.nih.gov Synergistic Cancer Therapy: An NIR-Activated Methylene Blue-Nitrogen Mustard Prodrug for Combined Chemotherapy and Photodynamic Therapy. pubmed.ncbi.nlm.nih.gov Synergic anti-tumor effects of photodynamic therapy and resveratrol on triple-negative breast cancer cells. pubmed.ncbi.nlm.nih.gov Spectroscopic Study of Methylene Blue Interaction with Coenzymes and its Effect on Tumor Metabolism. pubmed.ncbi.nlm.nih.gov A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas. pubmed.ncbi.nlm.nih.gov Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells.

Hydroxychloroquine

492 sources

Showing 6 of 492

pubmed.ncbi.nlm.nih.gov POLYPHARMACY, DRUG RELATED NITROSAMINE CONTAMINATION (BISOPROLOL/PROPAFENONE) AND THE LINK TO LICHEN PLANUS/SUBSEQUENT DEVELOPMENT OF KERATINOCYTE AND MUCOSAL CANCER/ORAL LEUKOPLAKIA: PRESENTATION OF THE FIRST CASE AND UPDATE ON THE NEW PATHOGENETIC VISION. pubmed.ncbi.nlm.nih.gov Raddeanin A promotes the apoptosis of gastric cancer in conjunction with autophagy inhibitor Hydroxychloroquine via MAPK signaling pathway. pubmed.ncbi.nlm.nih.gov Dermatomyositis as the First Manifestation of Nasopharyngeal Carcinoma-A Rare Case Report. pubmed.ncbi.nlm.nih.gov Co-inhibition of RAGE and TLR4 sensitizes pancreatic cancer to irreversible electroporation in mice by disrupting autophagy. pubmed.ncbi.nlm.nih.gov REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. pubmed.ncbi.nlm.nih.gov Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer.

Edited Oct 1, 2026